SLU-PP-332 Half-Life and Pharmacokinetics: What Studies Report

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), often described in secondary coverage as an "exercise mimetic." A common search around it asks for a half-life number. This page sets out what the verified published literature actually reports about the compound's metabolic fate and analytical behaviour, and — just as importantly — what it does not report. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment.

What "pharmacokinetics" means in this context

Pharmacokinetics describes what a body does to a compound: absorption (how much enters systemic circulation and how fast), distribution (where it goes and how extensively it partitions into tissues), metabolism (how it is chemically transformed, usually by hepatic enzymes) and excretion (how the parent compound and its metabolites leave). Half-life — the time for plasma concentration to fall by half during the terminal elimination phase — is a derived parameter. It is calculated from a measured concentration-time curve in a defined species, by a defined route, at a defined dose.

That definition matters here. A half-life value cannot be inferred from receptor pharmacology, from potency data, or from the fact that a compound is metabolised in a test tube. It requires in vivo sampling. Where that sampling has not been published for a compound, the honest answer to "what is the half-life" is that the parameter has not been reported in the accessible literature — not that it is short, long, or comparable to some other molecule.

What the verified literature covers

Three peer-reviewed papers form the verified evidence base for this page. All three are recent, and all three sit closer to analytical chemistry and medicinal chemistry than to clinical pharmacology.

In vitro metabolite identification for doping control

Researchers characterised the in vitro metabolites of SLU-PP-332 in work framed explicitly around doping-control purposes, describing the compound as an ERRα/β/γ agonist and identifying the products formed when it was incubated in in vitro systems (PMID 41688415). The stated objective of that study was analytical: to generate the metabolite information that testing laboratories need in order to detect use of the compound, rather than to describe how long it persists in a dosed organism.

A second paper took a parallel approach across two related molecules, reporting in vitro metabolism and analytical characterisation of both SLU-PP-332 and SLU-PP-915 and describing them as novel pan-ERR agonists with doping potential (PMID 41588687). Again, the study's framing was detection-oriented — establishing analytical signatures and metabolic products — rather than quantifying systemic exposure over time.

These two studies are genuinely informative about one leg of pharmacokinetics: biotransformation. If a compound is extensively metabolised in vitro, that is a signal that hepatic clearance is likely to be a meaningful elimination route. But in vitro metabolite identification does not, on its own, yield clearance in mL/min/kg, volume of distribution, oral bioavailability, or a terminal half-life. Those require in vivo work, and the verified record summarised here does not contain a human study of that kind.

Medicinal-chemistry optimisation of the scaffold

A third paper described chemical optimisation of SLU-PP-332 as an exercise mimetic, with the stated purpose of enabling insight into estrogen-related receptor signalling (PMID 41850449). Optimisation programmes of this type typically iterate on a starting compound to improve its properties as a research tool. The relevance to pharmacokinetics is indirect but real: the existence of an optimisation effort around a chemical series is generally read as evidence that the original molecule was treated as a starting point rather than a finished agent. What the paper reports about specific drug-like properties is limited to what appears in its published scope, and this page does not extrapolate beyond that.

Evidence map: what was studied, in what system

Absorption: what is and is not on the record

Oral bioavailability is a route-specific, species-specific measurement. It is obtained by comparing systemic exposure after oral administration with exposure after intravenous administration in the same species. None of the three verified papers is a bioavailability study, and none of them is described as reporting a human oral exposure measurement. Claims circulating outside the peer-reviewed literature that assign SLU-PP-332 a particular oral absorption percentage or a particular time to peak concentration are not traceable to the verified sources cited here.

It is worth separating two distinct questions that frequently get merged online. The first is whether a compound is absorbed at all by a given route. The second is how much of an administered amount reaches circulation intact and how quickly. The in vitro metabolism papers speak to neither directly; they speak to what happens once the molecule encounters metabolising enzymes (PMID 41588687).

Distribution: unreported in the verified record

Volume of distribution, plasma protein binding, tissue partitioning and central-nervous-system penetration are all standard distribution parameters. The verified papers summarised here are an in vitro metabolite study, a combined in vitro metabolism and analytical characterisation study, and a medicinal-chemistry optimisation study; distribution measurements are not within the reported scope of any of them (PMID 41688415, PMID 41850449). Anyone encountering a stated volume of distribution for this compound should be able to trace it to a primary in vivo source; the verified set here is not that source.

Metabolism and clearance: the best-characterised leg

Metabolism is the part of the pharmacokinetic picture where published data genuinely exist. Both doping-control papers were designed to establish which metabolic products form and how they can be measured analytically (PMID 41688415, PMID 41588687). In anti-doping science this is a standard and necessary first step: laboratories must know what to look for in a sample, and metabolites are frequently more informative analytical targets than the parent compound because they can persist in urine after the parent has fallen below detection limits.

Two implications follow, and both are about detection rather than about physiology:

• Detection windows are not half-lives. The length of time an analyte remains measurable depends on assay sensitivity, matrix (urine versus blood), sample handling, and the amount administered — not solely on elimination kinetics. A metabolite characterisation study establishes targets for detection; it does not establish a half-life.
• In vitro metabolic stability is a predictor, not a measurement. Microsomal or hepatocyte incubations are used across drug discovery to rank compounds for likely hepatic clearance. They inform expectations. They are routinely followed by in vivo studies precisely because in vitro-to-in vivo extrapolation is imperfect.

Because both papers are framed around doping potential, the practical reason this analytical work was done is regulatory: sports anti-doping programmes need methods for non-approved substances that circulate in performance contexts. SLU-PP-332 is a research compound; it is not an approved medicine in the United States or the European Union, and materials of this type are generally distributed for research use only. Nothing on this page should be read as legal advice.

Species and route: where the gaps are

A useful habit when reading pharmacokinetic claims is to ask three questions of every number: which species, which route, and which dose. For SLU-PP-332, applying those questions to the verified literature produces the following picture:

1. Species. The verified papers report in vitro work and chemical optimisation. No human pharmacokinetic dataset appears among them.
2. Route. Because the published work summarised here is in vitro and synthetic-chemistry based, route-dependent parameters — oral, intraperitoneal, subcutaneous or intravenous exposure — are not reported in these sources.
3. Dose. This page states no dose for SLU-PP-332, because no dose falls within the reported scope of the three verified papers cited.

This is a meaningful gap rather than a technicality. Half-life estimates that circulate for research chemicals are frequently derived from preclinical rodent data and then repeated without the species label attached, or are back-calculated from anecdote. Neither practice produces a human parameter.

Adverse Events: What Studies Report

The three verified papers are in vitro metabolism, analytical characterisation and medicinal-chemistry optimisation studies (PMID 41688415, PMID 41588687, PMID 41850449). Safety monitoring in humans — the collection of treatment-emergent adverse events, laboratory abnormalities and tolerability data — is the product of clinical trials, and no such trial appears among these sources. The absence of reported adverse events in in vitro chemistry papers is not evidence of safety; it reflects the fact that those study designs cannot generate safety data at all.

How to read a half-life claim about this compound

When a specific figure is encountered, a few checks separate sourced numbers from repeated ones:

• Is a primary citation given, and does that citation contain a concentration-time analysis rather than a receptor assay?
• Is the species named, and is the route named?
• Is the figure a terminal half-life, an in vitro metabolic half-life in a microsomal incubation, or a detection window from an anti-doping method? These are three different quantities that share a similar-sounding name.
• Does the source distinguish SLU-PP-332 from related analogues such as SLU-PP-915, which was characterised alongside it in one study (PMID 41588687) and from the optimised compounds generated in the chemistry programme (PMID 41850449)? Analogues within a series can differ substantially in metabolic stability.

Bottom line

The published record that is verifiable for SLU-PP-332 describes how the molecule is metabolised in vitro, how it and a close analogue can be detected analytically, and how the chemical scaffold was optimised to interrogate ERR signalling. Researchers in those studies reported metabolite identities and analytical characteristics; the study designs did not extend to human plasma kinetics. Consequently, a human half-life, human oral bioavailability, human volume of distribution and human clearance for SLU-PP-332 are not established in the verified literature summarised here. Readers evaluating claims to the contrary should look for a primary in vivo pharmacokinetic citation with species, route and dose attached.

References

• Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling (International Journal of Biological Macromolecules, 2026)
• Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes (Drug Testing and Analysis, 2026)
• In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential (Rapid Communications in Mass Spectrometry, 2026)